JP2020191882A5 - - Google Patents

Download PDF

Info

Publication number
JP2020191882A5
JP2020191882A5 JP2020119962A JP2020119962A JP2020191882A5 JP 2020191882 A5 JP2020191882 A5 JP 2020191882A5 JP 2020119962 A JP2020119962 A JP 2020119962A JP 2020119962 A JP2020119962 A JP 2020119962A JP 2020191882 A5 JP2020191882 A5 JP 2020191882A5
Authority
JP
Japan
Prior art keywords
light chain
mammal according
transgenic murine
nucleic acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020119962A
Other languages
English (en)
Japanese (ja)
Other versions
JP7242611B2 (ja
JP2020191882A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020191882A publication Critical patent/JP2020191882A/ja
Publication of JP2020191882A5 publication Critical patent/JP2020191882A5/ja
Priority to JP2022147656A priority Critical patent/JP7439201B2/ja
Application granted granted Critical
Publication of JP7242611B2 publication Critical patent/JP7242611B2/ja
Priority to JP2024020295A priority patent/JP2024063038A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020119962A 2008-06-27 2020-07-13 抗体産生非ヒト哺乳動物 Active JP7242611B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022147656A JP7439201B2 (ja) 2008-06-27 2022-09-16 抗体産生非ヒト哺乳動物
JP2024020295A JP2024063038A (ja) 2008-06-27 2024-02-14 抗体産生非ヒト哺乳動物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NLPCT/NL2008/050430 2008-06-27
NL2008050430 2008-06-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017078941A Division JP6824807B2 (ja) 2008-06-27 2017-04-12 抗体産生非ヒト哺乳動物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022147656A Division JP7439201B2 (ja) 2008-06-27 2022-09-16 抗体産生非ヒト哺乳動物

Publications (3)

Publication Number Publication Date
JP2020191882A JP2020191882A (ja) 2020-12-03
JP2020191882A5 true JP2020191882A5 (2) 2022-03-08
JP7242611B2 JP7242611B2 (ja) 2023-03-20

Family

ID=41280336

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011516168A Active JP5749161B2 (ja) 2008-06-27 2009-06-29 抗体産生非ヒト哺乳動物
JP2015097258A Pending JP2015156871A (ja) 2008-06-27 2015-05-12 抗体産生非ヒト哺乳動物
JP2017078941A Active JP6824807B2 (ja) 2008-06-27 2017-04-12 抗体産生非ヒト哺乳動物
JP2020119962A Active JP7242611B2 (ja) 2008-06-27 2020-07-13 抗体産生非ヒト哺乳動物
JP2022147656A Active JP7439201B2 (ja) 2008-06-27 2022-09-16 抗体産生非ヒト哺乳動物
JP2024020295A Pending JP2024063038A (ja) 2008-06-27 2024-02-14 抗体産生非ヒト哺乳動物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2011516168A Active JP5749161B2 (ja) 2008-06-27 2009-06-29 抗体産生非ヒト哺乳動物
JP2015097258A Pending JP2015156871A (ja) 2008-06-27 2015-05-12 抗体産生非ヒト哺乳動物
JP2017078941A Active JP6824807B2 (ja) 2008-06-27 2017-04-12 抗体産生非ヒト哺乳動物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022147656A Active JP7439201B2 (ja) 2008-06-27 2022-09-16 抗体産生非ヒト哺乳動物
JP2024020295A Pending JP2024063038A (ja) 2008-06-27 2024-02-14 抗体産生非ヒト哺乳動物

Country Status (23)

Country Link
EP (7) EP2147594B1 (2)
JP (6) JP5749161B2 (2)
KR (5) KR101990228B1 (2)
CN (3) CN112481300A (2)
AU (1) AU2009263082C1 (2)
CA (1) CA2729095C (2)
CY (2) CY1114830T1 (2)
DK (4) DK2147594T3 (2)
ES (4) ES2906344T3 (2)
FI (1) FI3456192T3 (2)
HR (3) HRP20220205T1 (2)
HU (1) HUE057994T2 (2)
LT (2) LT3456192T (2)
MX (1) MX2010014542A (2)
NZ (1) NZ590118A (2)
PL (3) PL3456192T3 (2)
PT (4) PT2147594E (2)
RS (3) RS67450B1 (2)
RU (2) RU2731084C2 (2)
SG (3) SG10201408500RA (2)
SI (3) SI2147594T1 (2)
WO (1) WO2009157771A2 (2)
ZA (1) ZA201009312B (2)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
EP2147594B1 (en) * 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK3622815T3 (da) * 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SMT202600080T1 (it) * 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
AU2013204019B2 (en) * 2010-02-08 2014-02-27 Regeneron Pharmaceuticals, Inc. Common light chain mouse
ES2984483T3 (es) 2010-03-31 2024-10-29 Ablexis Llc Ingeniería genética de ratones para la producción de anticuerpos quiméricos
CN103228130B (zh) * 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
SMT201700023T1 (it) * 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
ES2791758T3 (es) 2011-12-22 2020-11-05 Hoffmann La Roche Organización de vectores de expresión, procedimientos de generación de células de producción novedosos y su uso para la producción recombinante de polipéptidos
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
MX353278B (es) * 2012-03-06 2018-01-05 Regeneron Pharma Raton con cadena ligera comun.
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
MX2014014891A (es) * 2012-06-05 2015-06-17 Regeneron Pharma Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
CN103571872B (zh) * 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
EP4545567A3 (en) * 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
ES2613379T3 (es) * 2013-10-15 2017-05-24 Regeneron Pharmaceuticals, Inc. Animales con IL-15 humanizada
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
GB2526867A (en) * 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
ES2905569T3 (es) 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US9914777B2 (en) 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
JP2018525007A (ja) 2015-08-24 2018-09-06 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． 免疫グロブリンの産生増強
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
EP4414484A3 (en) 2016-02-04 2025-01-15 Trianni, Inc. Enhanced production of immunoglobulins
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
BR112019002771A2 (pt) 2016-08-12 2019-05-14 Oxitec Ltd polinucleotídeo de módulo de controle de união de doublesex, sistema de expressão de gene, plasmídeo vetor de expressão, inseto geneticamente engenheirado, métodos para produzir insetos geneticamente engenheirados, para cultivar seletivamente insetos macho geneticamente engenheirados, para reduzir uma população de inseto selvagem, para criar um mosquito aedes aegypti transgênico e para detectar a presença de uma molécula de dna, local alvo cromossômico de aedes aegypti, mosquito aedes aegypti geneticamente engenheirado, molécula de dna, e, kit de detecção de dna.
ES2981272T3 (es) 2016-09-23 2024-10-08 Merus Nv Moléculas de unión que modulan una actividad biológica expresada por una célula
CA3094322A1 (en) * 2017-03-20 2018-09-27 Washington University Cells and methods of uses and making the same
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
MX2019011658A (es) 2017-03-31 2019-11-18 Merus Nv Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
CN118027197A (zh) 2017-07-06 2024-05-14 美勒斯公司 调节由细胞表达的生物活性的抗体
MX2020000055A (es) 2017-07-06 2020-08-06 Merus Nv Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
AU2018296067B2 (en) 2017-07-06 2021-06-10 Merus B.V. Binding molecules that modulate a biological activity expressed by a cell
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
WO2019108065A1 (en) 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
HUE060608T2 (hu) * 2017-12-05 2023-03-28 Regeneron Pharma Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
TWI890481B (zh) 2018-02-09 2025-07-11 日商小野藥品工業股份有限公司 雙特異性抗體
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
AR117409A1 (es) 2018-03-29 2021-08-04 Oxitec Ltd Noctuidas autolimitantes
MA52212A (fr) 2018-03-30 2021-02-17 Merus Nv Anticorps multivalent
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
JP7269963B2 (ja) 2018-06-08 2023-05-09 クリスタル バイオサイエンス インコーポレイテッド 同じ軽鎖ｉを有する多様な抗体を産生するためのトランスジェニック動物
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US11873338B2 (en) 2018-12-20 2024-01-16 Merus N.V. CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
US12467062B2 (en) 2018-12-21 2025-11-11 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
JP7443376B2 (ja) * 2018-12-31 2024-03-05 メルス ナムローゼ フェンノートシャップ 混合結合ドメイン
CA3124688A1 (en) 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
MA54943A (fr) 2019-02-14 2021-12-22 Merus Nv Production de compositions comprenant deux anticorps ou plus
EP3924384A1 (en) 2019-02-14 2021-12-22 Merus N.V. Combinations of binding moieties that bind egfr, her2 and her3
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
TW202546002A (zh) 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
TWI862565B (zh) * 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
AU2020268684C1 (en) 2019-05-09 2026-04-02 Merus B.V. Variant domains for multimerizing proteins and separation thereof
CN114502725B (zh) * 2019-07-01 2025-09-12 特里安尼公司 转基因哺乳动物及使用方法
JP6881658B2 (ja) * 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
TW202118790A (zh) * 2019-07-30 2021-05-16 日商小野藥品工業股份有限公司 雙特異性抗體
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
JP7536085B2 (ja) 2019-08-19 2024-08-19 メルス ナムローゼ フェンノートシャップ Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
US20220409732A1 (en) 2019-12-02 2022-12-29 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CN116199780A (zh) 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
IL294368A (en) 2020-01-29 2022-08-01 Merus Nv Means and method for modulating mixed effects in immune cells
TW202206460A (zh) 2020-04-24 2022-02-16 荷蘭商美勒斯公司 使用結合lgr5及egfr之抗體的癌症治療
JP2023529846A (ja) * 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
JP7714992B2 (ja) * 2020-10-02 2025-07-30 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
CN117624324A (zh) 2020-12-15 2024-03-01 美勒斯公司 利用结合lgr5和egfr的抗体治疗癌症
CA3202416A1 (en) 2020-12-16 2022-06-23 Pieter Fokko VAN LOO Multispecific antibodies for the treatment of cancer
CN116848254B (zh) 2020-12-16 2026-03-17 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
US20240058444A1 (en) 2020-12-18 2024-02-22 Merus N.V. Antibody composition
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
US20240425604A1 (en) 2021-10-06 2024-12-26 Merus N.V. Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
CN118632872A (zh) 2022-01-25 2024-09-10 美勒斯公司 用于治疗癌症的组合疗法
US20250188171A1 (en) 2022-03-07 2025-06-12 Merus N.V. Combination therapy including antibodies that bind egfr and cmet
KR20240151848A (ko) 2022-03-07 2024-10-18 메뤼스 엔.페. Egfr 및 cmet에 결합하는 항체를 사용한 치료
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
AU2023408531A1 (en) 2022-12-23 2025-07-17 Merus B.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
TW202432606A (zh) 2022-12-28 2024-08-16 荷蘭商美勒斯公司 使用結合egfr的抗體及細胞毒性藥物的組合之癌症治療
WO2025105961A1 (en) 2023-11-17 2025-05-22 Merus N.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4531078A (en) 1983-10-27 1985-07-23 Polaroid Corporation Control circuit for electronic flash
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
WO1993012227A1 (en) * 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
KR20010042329A (ko) * 1998-03-30 2001-05-25 와일러 제임스 에프. 코르티코트로핀 방출 인자 수용체 1-결핍 마우스
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1789416B (zh) * 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
DK2314629T4 (da) * 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
EP1439234A1 (en) * 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
AU2006242854A1 (en) * 2005-04-29 2006-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
AU2007235496B2 (en) * 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2147594B1 (en) * 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
SMT202600080T1 (it) * 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
IT202300006069A1 (it) 2023-03-29 2024-09-29 Comecer Spa Contenitore modulare per trasportare radiofarmaci o farmaci termolabili

Similar Documents

Publication Publication Date Title
JP2020191882A5 (2)
DK1461442T3 (en) Transgenic animals with human Ig lambda light chain genes
Schusser et al. Immunoglobulin knockout chickens via efficient homologous recombination in primordial germ cells
Brüggemann et al. Human antibody production in transgenic animals
US10575504B2 (en) Non-human mammals for the production of chimeric antibodies
Schusser et al. Expression of heavy chain‐only antibodies can support B‐cell development in light chain knockout chickens
JP2020202873A (ja) 限定された免疫グロブリン重鎖のマウス
RU2011102962A (ru) Продуцирующие антитела млекопитающие, не являющиеся человеком
Satofuka et al. Efficient human-like antibody repertoire and hybridoma production in trans-chromosomic mice carrying megabase-sized human immunoglobulin loci
JP2016127840A (ja) 修飾された免疫グロブリン重鎖配列を有する非ヒト動物
HUE027949T2 (en) Non-human animals expressing antibodies having a common light chain
Sano et al. Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle
HUE031903T2 (en) Mice producing VL binding proteins
Zeng et al. Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells
Lee et al. Development and characterization of a CRISPR/Cas9-mediated RAG1 knockout chicken model lacking mature B and T cells
Sinkora et al. Comparative aspects of immunoglobulin gene rearrangement arrays in different species
Goodnow et al. Clonal silencing of self-reactive B lymphocytes in a transgenic mouse model
CN118946265A (zh) 具有人源化免疫球蛋白和mhc基因座的经基因修饰的非人动物
CA2752681A1 (en) Hyper ige animal model with enhanced immunoglobulin heavy chain class switching to c-epsilon
CN118383328B (zh) B细胞特异性敲除Ewsr1基因的小鼠模型构建方法及应用
WO2026040501A1 (zh) 用于制备共同轻链的基因修饰的啮齿动物及其制备方法
Erickson A Novel B-1b Precursor Stage in the Peritoneal Cavity
AU2024354039A1 (en) Genetically modified non-human animals with humanized immunoglobulin locus
CN121592712A (zh) 用于制备共同轻链的基因修饰的啮齿动物及其制备方法
HK40050013A (en) Transgenic mice for the production of chimeric antibodies